- Home
- BLUE
BLUE
bluebird bio Inc.
as 03-31-2025 12:32pm EST
bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.
| Founded: | 1992 | Country: | United States |
| Employees: | N/A | City: | SOMERVILLE |
| Market Cap: | 36.9M | IPO Year: | 2013 |
| Target Price: | $51.00 | AVG Volume (30 days): | 318.1K |
| Analyst Decision: | Hold | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -24.84 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.56 - $28.60 | Next Earning Date: | 03-27-2025 |
| Revenue: | $83,807,000 | Revenue Growth: | 184.12% |
| Revenue Growth (this year): | 208.55% | Revenue Growth (next year): | 19.79% |
Stock Insider Trading Activity of bluebird bio Inc. (BLUE)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Klima Thomas J | BLUE | See Remarks | Mar 3 '25 | Sell | $3.92 | 500 | $1,959.70 | 7,878 | |
| Obenshain Andrew | BLUE | President and CEO | Mar 3 '25 | Sell | $3.92 | 921 | $3,609.77 | 18,327 | |
| Colvin Richard A | BLUE | Chief Medical Officer | Mar 3 '25 | Sell | $3.92 | 584 | $2,288.93 | 7,610 | |
| Klima Thomas J | BLUE | See Remarks | Feb 3 '25 | Sell | $7.39 | 122 | $901.89 | 7,878 | |
| Obenshain Andrew | BLUE | President and CEO | Feb 3 '25 | Sell | $7.39 | 86 | $635.76 | 18,327 | |
| Colvin Richard A | BLUE | Chief Medical Officer | Feb 3 '25 | Sell | $7.39 | 64 | $473.12 | 7,610 | |
| Vittiglio Joseph | BLUE | Chief Business & Legal Officer | Feb 3 '25 | Sell | $7.39 | 238 | $1,759.42 | 4,501 | |
| Obenshain Andrew | BLUE | President and CEO | Jan 6 '25 | Sell | $9.24 | 140 | $1,293.60 | 18,327 | |
| Colvin Richard A | BLUE | Chief Medical Officer | Jan 6 '25 | Sell | $9.24 | 19 | $175.56 | 7,610 |
Latest bluebird bio Inc. News
BLUE Breaking Stock News: Dive into BLUE Ticker-Specific Updates for Smart Investing
MT Newswires
3 days ago
Bluebird Bio Gets Rival Buyout Proposal From Ayrmid; Shares Jump After Hours
Business Wire
3 days ago
bluebird bio Confirms Receipt of an Unsolicited Non-Binding Proposal from Ayrmid
Zacks
4 days ago
Bluebird Bio (BLUE) Reports Q4 Loss, Tops Revenue Estimates
Pharmaceutical Technology
a month ago
Struggling bluebird bio to go private for less than $30m
Benzinga
a month ago
What's Going On With Gene Therapy Company Bluebird Bio Stock Today?
Business Wire
a month ago
bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital
Insider Monkey
3 months ago
bluebird bio, Inc. (BLUE): Is This Gene Therapy Stock a Good Buy Right Now?
Business Wire
4 months ago
bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition
Compare BLUE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BLUE bluebird bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.